RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles is door Industry Standard Research (ISR) uitgeroepen tot brancheleider in dienstverlening voor medisch onderzoek in de eerste, tweede, derde en vierde fase. Dat heeft ISR schrijft in zijn rapporten CRO Quality Benchmarking — Phases I, II/III and IV 2016. Quintiles is op basis van servicekwaliteit ook uitgeroepen tot beste dienstverlener binnen alle fases voor klinische ontwikkeling als het gaat om differentiatie. Bovendien wordt Quintiles in drie rapporten aangemerkt als meest gebruikte dienstverlener voor onderzoek in de eerste, tweede en derde en vierde fase.
“In het huidige complexe en onderling verbonden medische landschap, vereist succes een grotere schaal, meer specialisering en efficiëntie dan voorheen”, zei Kevin Gordon, operationeel bestuurder van Quintiles . “We zijn vereerd met de erkenning van ons leiderschap in alle fases van klinische ontwikkeling in de CRO-rapporten van ISR. Deze erkenning onderstreep Quintiles’ vermogen tot de koppeling van expertise voor de verwezenlijking van waardeverhoging voor onze klanten en de patiënten die we uiteindelijk samen helpen.”
CORRECTING and REPLACING Quintiles Recognized as Industry Leader for Phase I, Phase II/III and Phase IV Services
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles has been named the industry leader in Phase I, Phase II/III and Phase IV services, according to the Industry Standard Research’s (ISR) 2016 CRO Quality Benchmarking — Phases I, II/III and IV reports. Quintiles also was named the best service provider across all phases of clinical development for differentiation based on service quality and was identified as the most used provider of Phase I, Phase II/III and Phase IV services, according to the three reports.
“In today’s complex and interconnected healthcare landscape, success requires a higher degree of scale, specialization and efficiency than ever before,” said Quintiles Chief Operating Officer Kevin Gordon. “We are honored to be recognized for our industry leadership across all phases of clinical development in ISR’s 2016 CRO benchmarking reports. This recognition underscores Quintiles’ ability to connect capabilities and expertise across our global enterprise to deliver the highest value for our customers and the patients we ultimately serve together.”
Quintiles received the highest scores among large CROs on metrics for overall satisfaction, likelihood of using again and likelihood of recommending, culminating in the highest “loyalty” score for Phase II/III services.
“We are honored to be recognized as the industry leaders in Phase II/III services for the fifth year in a row,” said Cynthia Verst, president of Clinical Operations at Quintiles. “Customers come to Quintiles to leverage our deep therapeutic and operational experience, innovative data and technological capabilities and operational excellence. This award reflects the talented, passionate employees who provide unique insight and superior delivery to improve our customers’ probability of success.”
Quintiles was top-rated among CROs for Phase II/III and Phase IV in regards to global footprint and breadth of services. Quintiles has the necessary local knowledge, experience and resources to help customers successfully execute trials throughout the world and can deliver value by leveraging real-world evidence and insights across the entire drug development process.
“The success for a product does not stop at market approval,” said Andrea Spannheimer, senior vice president and global head, Real-World & Late Phase Research at Quintiles. “With an excellent record of post-marketing research success, Quintiles stands ready to help our customers reach their products’ potential by asking the right questions and applying real-world evidence across the product development process and beyond to get the right answers. We are honored to be recognized for our exemplary Phase IV services by ISR reports for the fourth year in a row.”
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the Fortune 500 and has been named to Fortune’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.